QNCX Quince Therapeutics
- 1.070
- +0.015+1.42%
- 1.060
- -0.010-0.93%
Quince Therapeutics News
Express News | Quince Therapeutics Q4 EPS $(0.21) Down From $(0.13) YoY
Quince Therapeutics Reported $75.1M in Cash as of December 31, 2023, Expect to Fully Fund Lead Asset, EryDex, Through Phase 3 NEAT Topline Results and Prepare for a Potential NDA Submission in 2026
Strong Cash Position Expected to Support Meaningful Clinical MilestoneReported $75.1 million in cash, cash equivalents, and short-term investments as of December 31, 2023. Quince expects its existing
Press Release: Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 01, 2024-- Quince Therapeutics, Inc. (Na
Quince Therapeutics Launches Scientific Advisory Board
World-renowned scientists and clinicians to provide expert insight and advice to support advancement of the company's lead Phase 3 asset, new indications, and pipeline expansion Quince Therapeutics, Inc.
Quince Therapeutics Appoints Rajiv Patni to Board of Directors
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to Its Board of Directors
Quince Therapeutics, Inc. (NASDAQ:QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient's own biology to deliver rare disease therapeutics, today announced
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$QNCX--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a pat
Quince Therapeutics to Participate at Investor Events in January 2024
Quince Therapeutics On Dec. 22 Board Approved Certain Mutual Termination Of License Agreement By And Between Co, Purdue Research Foundation
Quince Therapeutics On Dec. 22 Board Approved Certain Mutual Termination Of License Agreement By And Between Co, Purdue Research Foundation
Quince Therapeutics(QNCX.US) Director Buys US$69,232.62 in Common Stocks
$Quince Therapeutics(QNCX.US)$ Director Lamond David purchased 67,881 shares of Common Stocks on Dec 12, 13, 14, 2023 at an average price of $1.02 for a total value of $69,232.62.Source: Announcement
SHF Holdings And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones closed higher by over 60 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interes
Quince Therapeutics(QNCX.US) Director Buys US$58,133.92 in Common Stocks
$Quince Therapeutics(QNCX.US)$ Director Lamond David purchased 57,369 shares of Common Stocks on Dec 5, 6, 7, 2023 at an average price of $1.01 for a total value of $58,133.92.Source: Announcement Wha
Over $2M Bet On This Industrial Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed higher by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders intere
Quince Therapeutics(QNCX.US) Director Buys US$40,545.96 in Common Stocks
$Quince Therapeutics(QNCX.US)$ Director Lamond David purchased 43,134 shares of Common Stocks on Nov 29, 30, Dec 1, 2023 at an average price of $0.94 for a total value of $40,545.96.Source: Announceme
Quince Therapeutics Completes Acquisition Of EryDel S.P.A. >QNCX
Quince Therapeutics Completes Acquisition Of EryDel S.P.A. >QNCX
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold
By Denny Jacob Quince Therapeutics said it intends to advance trials on EryDex following the U.S. Food and Drug Administration's hold being lifted on EryDel's investigational new drug application. T
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel's Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced that the U.S. Food and Drug
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
Quince Therapeutics, Inc. (NASDAQ:QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients' lives, today announced the appointment of Charles
Quince Therapeutics(QNCX.US) Director Buys US$107.9K in Common Stocks
$Quince Therapeutics(QNCX.US)$ Director Lamond David purchased 82,052 shares of Common Stocks on Aug 30, 31, 2023 at an average price of $1.32 for a total value of $107.9K.Source: Announcement What is
Sidoti Events, LLC's Virtual August Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place
Analysis
Price Target
No Data
